Previous close | 10.40 |
Open | 10.40 |
Bid | 7.10 |
Ask | 9.80 |
Strike | 15.00 |
Expiry date | 2024-10-18 |
Day's range | 10.40 - 10.40 |
Contract range | N/A |
Volume | |
Open interest | 1 |
We have narrowed our search to five small-cap biotech stocks with strong potential for the rest of 2024. These are: ARQT, BCYC, CSTL, PRME, LXRX.
The average of price targets set by Wall Street analysts indicates a potential upside of 121% in Prime Medicine, Inc. (PRME). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced that Keith Gottesdiener, M.D., President and Chief Executive Officer will present at two upcoming investor conferences: Jefferies Healthcare Conference: Fireside chat on Wednesday, June 5, 2024, at 1:30 p.m. ET in New York, NY.Goldman Sachs 45th Annual Global Healthcare Conference